Evanston, Ill. – Researchers led by Northwestern University and the University of Wisconsin-Madison have introduced a pioneering approach aimed at combating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Amyotrophic lateral sclerosis (ALS). In a new study, researchers discovered a new way to enhance the body’s antioxidant response, which...
Latest News
Evanston, Illinois — A team of Northwestern University scientists has developed the first wireless, implantable temperature sensor to detect inflammatory flareups in patients with Crohn’s disease. The approach offers long-term, real-time monitoring and could enable clinicians to act earlier to prevent or limit the permanent damage caused by inflammatory episodes....
CHICAGO, Illinois — A genetic change or variant in a gene called SCN2A is a known cause of infantile seizures, autism spectrum disorder and intellectual disability, as well as a wide range of other moderate-to-profound impairments in mobility, communication, eating and vision. The severity of these disorders can vary widely...
South Bend, Indiana – Certain types of light have proven to be an effective, minimally invasive treatment for cancers located on or near the skin when combined with a light-activated drug. But deep-seated cancers, surrounded by tissue, blood and bone, have been beyond the reach of light’s therapeutic effects. To...
South Bend, Indiana – Researchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis. The crux of the diagnostic is a biochip that...
South Bend, Indiana – What could cancer teach us about tuberculosis? That’s a question Meenal Datta has been chasing since she was a graduate student. Once the body’s immune system is infected with tuberculosis, it forms granulomas — tight clusters of white blood cells — in an attempt to wall...
Notre Dame’s famous “Touchdown Jesus” mural lit up for Rare Disease Day on Tuesday.
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that results from its Phase 1b/2 clinical trial of NOUS-209 in Lynch Syndrome (LS) carriers have been published in Nature Medicine (D’Alise et...
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognize and eliminate cancer cells before tumors develop Final...
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation off-the-shelf and personalized neoantigen cancer immunotherapies, today announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. Following positive safety and immunogenicity data reported at...